Parallel Session I: Epidemiology
Post-Induction ANCA Titer Does Not Predict Relapse, Mortality, or Renal Outcomes: A Target Trial Emulation Study
Dr. Zachary Wallace
@zach_wallace_md
#Vasculitis22
What is AAV?
What about ANCA titres?
Biomarkers key in AAV
#Vasculitis22
Retrospective cohort study
PR3 or MPO AAV
3 outcomes of interest - death, ESKD or relapse
#Vasculitis22
Used an emulated target trial.
For more on that see below.
#Vasculitis22
Results
Flow chart
Baseline characteristics.
#Vasculitis22
Conclusions
Achieving serologic remission within 180 days of induction associated with decreased risk of relapse.
#Vasculitis22
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.